EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische Studie

Impact of Vancomycin-Resistant Enterococci (VRE)–Active Perioperative Prophylaxis in Liver Transplant Patients Colonized by VRE

Giulia Jole Burastero iD, Emmanuel Q Wey, Veronica Guidetti, Samuele Cantergiani, Valentina Menozzi, Davide Lo Porto, Andrea Cona, Amreen Khan iD, Valentina Serra, Giacomo Assirati iD, Giovanni Guaraldi iD, Giovanni Dolci iD und 9 weitere

Clinical Infectious Diseases · 2025

DOI: 10.1093/cid/ciaf121 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Clinical Infectious Diseases, 2025. Verfasst von Giulia Jole Burastero und 20 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Diseases Unit, Azienda Ospedaliero-Universitaria of Modena, Modena, Italy. Hauptthemen laut MEDLINE: Liver Transplantation, Vancomycin-Resistant Enterococci, Gram-Positive Bacterial Infections, Antibiotic Prophylaxis. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 34 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Data regarding the effectiveness of vancomycin-resistant Enterococci (VRE)–active prophylaxis for preventing early post–liver transplantation (LT) VRE infections in VRE-colonized patients are scarce.

Methods

131 pre-LT VRE-colonized patients who underwent LT were enrolled in a retrospective, observational, multicenter study. The incidence of early-onset VRE infections was compared between patients who received active prophylaxis for VRE and those who did not.

Results

Sixty-nine (52.7%) and 62 (47.3%) patients were enrolled in the VRE-active and non–VRE-active prophylaxis group. Tigecycline was the most common drug prescribed as VRE-active for prophylaxis (55/69; 79.7%). There was no significant difference in the number of patients who developed early-onset VRE infections in the VRE-active versus non–VRE-active groups at 7 (0 [0.0%] vs 2 [3.2%]; P = .222), 14 (4 [5.7%] vs 4 [6.4%]; P = 1.000), and 30 (6 [8.7%] vs 8 [12.9%]; P = .621) days post-LT, respectively. Risk of early-onset VRE infection within 30 days was not lower in the VRE-active group (log-rank P = .16 with Kaplan-Meier analysis; odds ratio [OR]: .643; 95% CI: .210–1.969; P = .439 with univariate analysis). Conversely, early infections caused by any pathogen were significantly lower in the VRE-active prophylaxis group compared with the control group (11 [15.9%] vs 20 [32.2%]; P = .047). Tigecycline prophylaxis was associated with a lower risk of early-onset infections with multivariate analysis (OR: .106; 95% CI: .015–.745; P = .024) and after adjusting for propensity score (adjusted OR: .146; 95% CI: .031–.708; P = .017).

Conclusions

VRE-active prophylaxis at LT did not reduce the incidence of early post-LT VRE infections and should not be recommended.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver TransplantationVancomycin-Resistant EnterococciGram-Positive Bacterial InfectionsAntibiotic ProphylaxisAnti-Bacterial AgentsHumansMaleFemaleMiddle AgedRetrospective StudiesAgedTigecyclineAdultIncidence

Stichwörter der Autor:innen

liver transplantperioperative antibiotic prophylaxispost-transplant early infectionstigecyclinevancomycin-resistant enterococci (VRE)

Substanzen

Anti-Bacterial AgentsTigecycline

Autor:innen und Institutionen

  • Infectious Diseases Unit, Azienda Ospedaliero-Universitaria of Modena, Modena, Italy.
  • Department of Infection, Royal Free London NHS Trust London, London, United Kingdom.
  • Centre for Clinical Microbiology, Division of Infection and Immunity, UCL, London, United Kingdom.
  • FIM Department, University of Modena and Reggio Emilia, Modena, Italy.
  • Unit of Infectious Disease, IRCCS-ISMETT Istituto di Ricovero e Cura a Carattere Scientifico-Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione, Palermo, Italy.
  • Department of Critical Care, Royal Free Hospital Pond St, London, United Kingdom.

ORCID-Profile: Giulia Jole Burastero, Amreen Khan, Giacomo Assirati, Giovanni Guaraldi, Giovanni Dolci, Marianna Meschiari, Adriana Cervo, Alessandra Mularoni, Erica Franceschini

Zitieren

APA

Burastero, G. J., Wey, E. Q., Guidetti, V., Cantergiani, S., Menozzi, V., Lo Porto, D., Cona, A., Khan, A., Serra, V., Assirati, G., Guaraldi, G., Dolci, G., Meschiari, M., Cervo, A., Tosi, M., Gruttadauria, S., Pollok, J. M., Di Benedetto, F., Mularoni, A., …, & Franceschini, E. (2025). Impact of Vancomycin-Resistant Enterococci (VRE)–Active Perioperative Prophylaxis in Liver Transplant Patients Colonized by VRE. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciaf121

Vancouver

Burastero GJ, Wey EQ, Guidetti V, Cantergiani S, Menozzi V, Lo Porto D, et al. Impact of Vancomycin-Resistant Enterococci (VRE)–Active Perioperative Prophylaxis in Liver Transplant Patients Colonized by VRE. Clinical Infectious Diseases. 2025. doi:10.1093/cid/ciaf121

BibTeX
@article{Burastero2025,
  author = {Burastero, Giulia Jole and Wey, Emmanuel Q and Guidetti, Veronica and Cantergiani, Samuele and Menozzi, Valentina and Lo Porto, Davide and Cona, Andrea and Khan, Amreen and Serra, Valentina and Assirati, Giacomo and Guaraldi, Giovanni and Dolci, Giovanni and Meschiari, Marianna and Cervo, Adriana and Tosi, Martina and Gruttadauria, Salvatore and Pollok, Joerg-Matthias and Di Benedetto, Fabrizio and Mularoni, Alessandra and Mussini, Cristina and Franceschini, Erica},
  title = {Impact of Vancomycin-Resistant Enterococci (VRE)–Active Perioperative Prophylaxis in Liver Transplant Patients Colonized by VRE},
  journal = {Clinical Infectious Diseases},
  year = {2025},
  doi = {10.1093/cid/ciaf121}
}
Kostenlos starten →